• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Shineco Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    7/17/24 5:25:14 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $SISI alert in real time by email
    false 0001300734 0001300734 2024-07-11 2024-07-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES AND EXCHANGE ACT OF 1934

     

    Date of report (date of earliest event reported): July 11, 2024

     

    SHINECO, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-37776   52-2175898

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    T1, South Tower, Jiazhaoye Square, Chaoyang District,
    Beijing, People’s Republic of China 100022

    (Address of principal executive offices)

     

    Registrant’s telephone number, including area code: (+86) 10-87227366

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each Class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock   SISI   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    On July 11, 2024, Shineco, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with EF Hutton LLC, as the representative (the “Representative”) for the underwriters listed on Schedule 1 thereto (the “Underwriters”), relating to the underwritten public offering (the “Offering”) of 1,869,160 shares of common stock, par value $0.001 per share of the Company (the “Shares”), at a public offering price of $1.07 per share, for aggregate gross proceeds of approximately $2.0 million, prior to deducting underwriting discounts and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 280,374 shares of its common stock at the public offering price per share, less the underwriting discounts to cover over-allotments, if any. EF Hutton LLC is acting as the sole book-running manager for the Offering.

     

    The Offering closed on July 15, 2024. The Company delivered the Shares to the Representative on the same day.

     

    The Shares were offered under the Company’s registration statement on Form S-3 (File No. 333-261229), initially filed with the U.S. Securities and Exchange Commission on November 19, 2021, as amended on May 11, 2022, and on June 3, 2022, and was declared effective on June 10, 2022 (the “Registration Statement”). A preliminary prospectus supplement to the Registration Statement in connection with the Offering was filed with the U.S. Securities and Exchange Commission on July 11, 2024, and a final prospectus supplement was filed on July 15, 2024.

     

    The aggregate gross proceeds of the Offering are approximately $2.0 million, prior to deducting underwriting discounts and other offering expenses. The net proceeds from the offering will be approximately $1.6 million, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. The Company intends to use approximately 50% of the net proceeds from the Offering for mergers and acquisitions, approximately 25% for repaying outstanding convertible notes, and 25% for general corporate purposes.

     

    Pursuant to the Underwriting Agreement, the Company agreed to an underwriting discount of 7.0% per Share, an additional cash fee equal to 0.5% of the gross proceeds raised by the Company in the Offering for non-accountable expenses, and also agreed to pay the expenses of the underwriters in connection with the Offering, including filing fees and underwriters’ counsel legal fees, up to an aggregate of $120,000.

     

    Our officers and directors, and certain 5% shareholders, have agreed, subject to certain exceptions, for a period of 180 days after the closing of this Offering, not to offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of common stock of the Company or any securities convertible into or exercisable or exchangeable for shares of common stock of the Company either owned as of the date of the Underwriting Agreement or thereafter acquired without the prior written consent of the Representative.

     

    We, and any successor, have agreed, subject to certain exceptions, not to for a period of ninety (90) days after the closing of the offering, (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of common stock of the Company or any securities convertible into or exercisable or exchangeable for shares of common stock of the Company; (ii) file or caused to be filed any registration statement with the SEC relating to the offering of any shares of common stock of the Company or any securities convertible into or exercisable or exchangeable for shares of common stock of the Company; (iii) complete any offering of debt securities of the Company, other than entering into a line of credit with a traditional bank, or other lending institution, which involves no issuance of any shares of common stock of the Company or any securities convertible into or exercisable or exchangeable for shares of common stock of the Company, or (iv) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of common stock of the Company.

     

    The Representative may, in their sole discretion and at any time or from time to time before the termination of the lock-up period, without notice, release all or any portion of the securities subject to lock-up agreements.

     

    The foregoing descriptions of the Underwriting Agreement and the form of lock-up agreement do not purport to be complete and is qualified in its entirety by reference to the full text of the Underwriting Agreement, a copy of which is attached hereto as Exhibit 1.1 and is incorporated herein by reference. A copy of the opinion of Hunter Taubman Fischer & Li LLC, as the U.S. counsel to the Company, regarding the legality of the issuance and sale of Shares is attached hereto as Exhibit 5.1.

     

    2

     

     

    This report shall not constitute an offer to sell or the solicitation to buy nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

     

    This report on Form 8-K is incorporated by reference into (i) the prospectus contained in the Company’s registration statement on Form S-3 (SEC File No. 333-261229) declared effective by the Securities and Exchange Commission (the “Commission”) on June 10, 2022; and (ii) the final prospectus supplement and accompanying prospectus relating to this Offering filed with the SEC on July 15, 2024.

     

    Item 8.01 Other Events.

     

    The Company issued press releases on July 12, 2024 in connection with the pricing of the Offering, and on July 15, 2024 in connection with the closing of the Offering. A copy of such press releases are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated herein by reference.

     

    Item 9.01 Financial Statements and Exhibits

     

    (d) Exhibits

     

    Exhibit No.   Description
    1.1   Underwriting Agreement by and between the Company and EF Hutton LLC, dated July 11, 2024
    5.1   Opinion of Hunter Taubman Fischer & Li LLC
    23.1   Consent of Hunter Taubman Fischer & Li LLC (included in Exhibit 5.1)
    99.1   Press Release titled “Shineco Announces Pricing of $2 Million Underwritten Public Offering” dated July 12, 2024
    99.2   Press Release titled “Shineco Announces Closing of $2 Million Underwritten Public Offering” dated July 15, 2024
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101).

     

    3

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Shineco Inc.
         
    Date: July 17, 2024 By: /s/ Jennifer Zhan
        Jennifer Zhan, Chief Executive Officer

     

    4

     

    Get the next $SISI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SISI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SISI
    SEC Filings

    View All

    Shineco Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events

    8-K - SHINECO, INC. (0001300734) (Filer)

    10/8/25 3:30:52 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form NT 10-K filed by Shineco Inc.

    NT 10-K - SHINECO, INC. (0001300734) (Filer)

    9/29/25 6:15:10 AM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    Shineco Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events

    8-K - SHINECO, INC. (0001300734) (Filer)

    7/30/25 7:35:46 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    $SISI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Shineco (SISI) Ignites Growth: $8.7M Tech Deal & Major Singapore Alliance Unleash Dual Engines

    BEIJING, Sept. 12, 2025 /PRNewswire/ -- Shineco Inc. (NASDAQ:SISI) ("Shineco" or the "Company"), a developer and commercializer of induced pluripotent stem cell (iPSC) technology platforms, today announced two major strategic advances. Its subsidiary, Xi'an Dong'ao Health Management Co., Ltd. ("Dong'ao Health"), has signed a technology services contract valued at US$8.7 million with Xinke Future Biotechnology (Bazhou) Co., Ltd. for the research and development of "microalgae-derived extracellular vesicles" technology. Separately, a delegation from Singapore's leading biotechnology company, BICC, completed a productive site visit to Dong'ao Health on September 10. The parties reached a broad

    9/12/25 9:30:00 AM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    Shineco Achieves Mass Production of High-Purity Physical Phospholipids, Breaking Foreign Monopoly and Unlocking Innovation Across Industries

    BEIJING, Sept. 10, 2025 /PRNewswire/ -- Shineco Inc. (NASDAQ:SISI) ("Shineco" or the "Company"), a leading developer of induced pluripotent stem cell (iPSC) technology platforms, today announced that its subsidiary, Fuzhou Meidashan Biotechnology Co., Ltd., has successfully achieved large-scale production of high-purity, highly active free-form soybean phospholipids. This breakthrough was made possible through its proprietary APCC-UF pure physical extraction technology, overcoming a persistent global technical challenge in the field. Testing by multiple authoritative institutions confirms that the product's key metrics meet internationally leading standards, providing robust technical suppor

    9/10/25 9:30:00 AM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    Shineco (NASDAQ: SISI) & BICC: From "Tech On-Chain" to "Global Redeemability"--RWA Ecosystem Takes Off for Long-Term Growth

    BEIJING, Aug. 27, 2025 /PRNewswire/ -- Shineco Inc. ((", Shineco", or the ", Company", , NASDAQ:SISI), a manufacturer of induced pluripotent stem cell (iPSC) technology platforms, has entered into a strategic cooperation agreement with Singapore-based BICC Pte Ltd to jointly promote the implementation and redemption of "on-chain cell assets" across multiple institutions and scenarios. This collaboration marks a new phase of "cross-enterprise redeemability" for cell assets on the blockchain, advancing the RWA ecosystem from "technical on-chain integration" to "real-world application. This partnership builds on Shineco's prior initiatives: establishing a Cell Digital Division,signing an agree

    8/27/25 6:30:00 AM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    $SISI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Huang Shanchun claimed ownership of 5,041,667 shares (SEC Form 3)

    3 - SHINECO, INC. (0001300734) (Issuer)

    4/24/25 4:05:15 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 3 filed by new insider Yan Chi Keung

    3 - SHINECO, INC. (0001300734) (Issuer)

    12/7/23 4:10:17 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 3 filed by new insider Wang Xiaohui

    3 - SHINECO, INC. (0001300734) (Issuer)

    12/7/23 4:10:16 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    $SISI
    Leadership Updates

    Live Leadership Updates

    View All

    Shineco Establishes Biological Cell Digital Division to Integrate Biological Cell Assets and Blockchain Technology

    BEIJING, Aug. 13, 2025 /PRNewswire/ -- Shineco Inc. ((", Shineco", or the ", Company", , NASDAQ:SISI), a manufacturer of induced pluripotent stem cell (iPSC) technology platforms, today announced the establishment of a Biological Cell Digital Business Division (the "Division"), and the appointment of Mr. Lin Hongguang as General Manager, to advance the integration of its biological cell assets and blockchain technology. Through a new architecture of blockchain-based cell assets, Shineco aims to build a vertical ecosystem within the biological cell sector, accelerate the global distribution of biological cell products and boost global sales. The Division is expected to use blockchain technol

    8/13/25 6:30:00 AM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    Future FinTech Announces the Appointment of Hu Li as the New CEO

    NEW YORK, Aug. 9, 2024 /PRNewswire/ -- Future Fintech Group Inc. (NASDAQ: FTFT), (hereinafter referred to as "Future FinTech", "FTFT" or the "Company"), a comprehensive financial and digital technology service provider, today announced that its Board of Directors (the "Board") approved the appointment of Mr. Hu Li as Chief Executive Officer ("CEO"), President and a member of the Board of the Company, effective August 5, 2024. Mr. Li will be fully responsible for the operation and management of the Company, helping it to expand internationally, manage its investment and financi

    8/9/24 9:00:00 AM ET
    $FTFT
    $SISI
    Real Estate
    Medicinal Chemicals and Botanical Products
    Health Care

    Shineco Announces the Appointment of Two New Executive Officers

    BEIJING, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (("Shineco" or the "Company", NASDAQ:SISI), a provider of technologically advanced healthcare products and services, announced today that its Board of Directors has appointed Ms. Xiaohui Wang and Mr. Chi Keung Yan as executive officers of the Company in key leadership roles. Effective November 13, 2023, Shineco's Board of Directors appointed Ms. Xiaohui Wang as Executive President of the Company. From March 2000 to November 2013, Ms. Wang was the founder and Chairperson of Chongqing Wintus (New Star) Enterprises Group, where she was responsible for its corporate planning, supervision of the group's business in the Chongqing region,

    11/17/23 9:00:00 AM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    $SISI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Shineco Inc.

    SC 13G/A - SHINECO, INC. (0001300734) (Subject)

    10/25/24 2:45:17 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D filed by Shineco Inc.

    SC 13D - SHINECO, INC. (0001300734) (Subject)

    7/12/24 5:28:03 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Shineco Inc.

    SC 13G - SHINECO, INC. (0001300734) (Subject)

    8/29/23 1:26:38 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care